Preeclampsia is a pregnancy-related condition characterized by elevated blood pressure and excess protein in the urine. It poses significant risks to both mothers and infants, often leading to premature and underweight births. Failure to diagnose preeclampsia early can result in complications such as preterm birth, organ failure, seizures, eclampsia, and potentially fatal outcomes for both mother and baby.
Recent advancements in diagnostic technologies, such as the Preecludia™ rule-out test and FDA-approved immunoassays, have enhanced early detection of preeclampsia. These innovations facilitate timely intervention and support clinical management, marking significant progress in addressing this severe pregnancy complication.
Preeclampsia is associated with risk factors such as advanced maternal age, obesity, and diabetes. Lifestyle choices, including inadequate diet, sedentary habits, alcohol consumption, and mental stress, contribute to the increasing occurrences of this condition during pregnancy.
North America currently leads the global market for preeclampsia diagnostics, attributed to rising healthcare expenditure, widespread adoption of advanced products, and government initiatives. The Asia-Pacific region is anticipated to grow at the highest rate due to factors like a high pregnancy rate, increased awareness about the disease, and a growing population.
The complex nature of preeclampsia requires a multidisciplinary approach, and the lack of awareness in developing countries poses a significant challenge. Additionally, insufficient awareness among healthcare providers about effective screening tools hinders market expansion in emerging countries.